---
title: CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell
  therapy and diminishes severity of CRS
date: '2023-10-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37879074/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231026180809&v=2.17.9.post6+86293ac
source: Blood
description: In the development of various strategies of anti-CD19 immunotherapy for
  treatment of B-cell malignancies, it remains unclear whether CD19 monoclonal antibody
  therapy impairs subsequent CD19-targeted chimeric antigen receptor T-cell (CART19)
  therapy. We evaluated the potential interference between the CD19-targeting monoclonal
  antibody tafasitamab and CART19 treatment in preclinical models. Concomitant treatment
  of tafasitamab and CART19 showed major CD19 binding competition, which led to ...
disable_comments: true
---
In the development of various strategies of anti-CD19 immunotherapy for treatment of B-cell malignancies, it remains unclear whether CD19 monoclonal antibody therapy impairs subsequent CD19-targeted chimeric antigen receptor T-cell (CART19) therapy. We evaluated the potential interference between the CD19-targeting monoclonal antibody tafasitamab and CART19 treatment in preclinical models. Concomitant treatment of tafasitamab and CART19 showed major CD19 binding competition, which led to ...